Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,967.38
(
1.18%
)
US TECH 100
25,134.00
(
1.78%
)
Dow Jones
48,535.99
(
0.66%
)
Brent Oil
92.69
(
-2.91%
)
Bitcoin
74,082.54
(
-0.56%
)
News Focus
News Focus
Post# of 257406
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122868
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 222330

Friday, 12/07/2018 8:15:45 AM

Friday, December 07, 2018 8:15:45 AM

Post# of 257406
AZN’s Imfinzi and Tremelimumab fail in second-line H&N cancer:

https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-the-phase-iii-eagle-trial-of-imfinzi-and-tremelimumab-in-advanced-head-and-neck-cancer-07122018.html

[Neither] Imfinzi monotherapy [nor] the combination of Imfinzi plus tremelimumab…[met]…the primary endpoints of improving OS compared to SoC chemotherapy…

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today